2025 Market Size And Company Share Data For Endometriosis
"The
Latest Research Report OpportunityAnalyzer: Endometriosis -
Opportunity Analysis and Forecast to 2025 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
About
Endometriosis Market
Endometriosis is an
estrogen-dependent, chronic, inflammatory disease characterized by
the appearance and growth of endometrial cells or tissues in
locations outside the uterus. It is a common gynecological condition;
however the disease is underdiagnosed due to the invasive nature of
laparoscopy that confirms diagnosis. GlobalData estimates the
endometriosis prevalence, including suspected and confirmed cases, to
grow from 9.6 million to 11.3 million worldwide between 2015 and
2025. Current FDA-approved therapies for endometriosis comprise drugs
that suppress ovulation and/or induce a hypoestrogenic state
including gonadotrophin-releasing hormone (GnRH) analogues,
progestins, and danazol. Off-label medical treatment for
endometriosis, commonly prescribed before definitive diagnosis is
made, include NSAIDs and hormonal contraceptives. The endometriosis
market will undergo a moderate growth from 1.72 billion to reach
sales of $2.04 billion over the 10-year period. This growth will
primarily be driven by the increasing diagnosed endometriosis
patients in the 7MM and the highly anticipated arrival of the novel
GnRH antagonist, elagolix, due to be released in the US and 5EU in
2018. Nevertheless, patent expiries of some branded drugs and the
sparsely populated endometriosis pipeline will curtail market growth
during the forecast period.
Highlights
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/959623
Key Questions Answered
- Oral contraceptives are among
the market leaders for endometriosis, prescribed off-label as
first-line of therapy to alleviate endometriosis-associated pain.
Second-line therapies, such as GnRH agonists, are effective
treatments; however their undesirable hypoestrogenic side effects and
failure to prevent symptom recurrence limit their use. Another
limitation of hormonal regimens is that their use prevents
conception. Therefore, there are considerably high unmet needs within
the indication. What are the main unmet needs in this market? Will
the drugs under development fulfil the unmet needs of the
endometriosis market?
- The current late-stage
endometriosis pipeline encompasses one novel therapeutic drug class,
GnRH antagonists, of which elagolix will be the first to enter the
market. Will the late-stage drugs make a significant impact on the
endometriosis market? Will elagolix become the market leader over the
10-year forecast period, and why?
- We have seen considerable
efforts over the past years to raise awareness and to identify
biomarkers for endometriosis. How will epidemiological changes impact
the growth of the future market?
Key Findings
- The main driver of moderate
growth in the endometriosis market will be the increase in the
diagnosed prevalence of endometriosis as well as the uptake of the
novel GnRH antagonist, elagolix.
- The major global barrier for the
endometriosis market will be the lack of entry of novel targeted
drugs that could be used safely as continuous therapy.
- The dynamics of the
endometriosis market will not change drastically over the next 10
years in terms of the current and future players in the endometriosis
market and GlobalData expects that AbbVie and Bayer will continue to
have a strong presence, as they are undertaking various strategies to
bring novel therapeutics into the endometriosis market. Other
companies with new chemical entities may also come near to surface by
the end of the forecast period.
- The endometriosis space has
considerable unmet needs. One of the largest unmet needs is a need
for therapies that would target the pathogenic processes of the
disease and have the potential to eradicate the disease and stop
recurrence. The market is in need for safe and effective long-term
therapies with minimal side effects that could also be given to
adolescent patients and/or patients with mild disease. Developing
therapies with non-contraceptive properties is also an untapped area
of the endometriosis market. Low diagnosis rates due to lack of
disease awareness and the lack of reliable noninvasive diagnostic
tools are major hurdles of successful treatment.
Scope
- Overview of endometriosis,
including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and treatment guidelines.
- Annualized endometriosis
therapeutics market revenue, annual cost of therapy and treatment
usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the endometriosis
therapeutics market.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and
future market competition in the global endometriosis therapeutics
market. Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies by
understanding the trends shaping and driving the global Endometriosis
therapeutics market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global Endometriosis
therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
Endometriosis therapeutics market from 2013-2023.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/959623
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 17
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
3 Disease Overview 21
3.1 Etiology 22
3.2 Pathophysiology 27
3.3 Symptoms and Diagnosis 29
3.4 Clinical Prognosis 34
3.5 Quality of Life 36
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities
38
4.3 Global Trends 39
4.3.1 US 40
4.3.2 5EU 41
4.3.3 Japan 41
4.4 Forecast Methodology 42
4.4.1 Sources Used Tables 45
4.4.2 Forecast Assumptions and
Methods 49
4.4.3 Sources Not Used 57
4.5 Epidemiological Forecast for
Endometriosis (2015-2025) 58
4.5.1 Diagnosed Incident Cases 58
4.5.2 Diagnosed Prevalent Cases 64
4.6 Discussion 72
4.6.1 Epidemiological Forecast
Insight 72
4.6.2 Limitations of the Analysis
73
4.6.3 Strengths of the Analysis 74
5 Current Treatment Options 75
5.1 Overview 75
5.2 GnRH Agonists 85
5.2.1 Zoladex (Goserelin Acetate)
85
5.2.2 Lupron Depot (Leuprolide
Acetate) 90
5.2.3 Synarel (Nafarelin Acetate
Nasal Spray) 95
5.2.4 Buserelin Acetate 98
5.2.5 Triptorelin 101
5.3 Progestins/Progestogens 104
5.3.1 Dienogest 104
5.3.2 Depo-SubQ Provera 104
(Medroxyprogesterone Injection) 111
5.4 Off-Label Treatment: Hormonal
Contraceptives, NSAIDs, and Aromatase Inhibitors 115
5.4.1 Hormonal Contraceptives 115
5.4.2 Nonsteroidal
Anti-inflammatory Drugs 119
5.4.3 Aromatase Inhibitors 121
6 Unmet Needs Assessment and
Opportunity Analysis 124
6.1 Overview 124
6.2 Noninvasive Diagnostics 126
6.2.1 Unmet Needs 126
6.2.2 Gap Analysis 129
6.2.3 Opportunity 134
6.3 Disease Awareness and
Education of Medical Professionals 138
6.3.1 Unmet Needs 138
6.3.2 Gap Analysis 141
6.3.3 Opportunity 144
6.4 More Effective Drugs with
Long-Term Safety and Tolerability 145
6.4.1 Unmet Needs 145
6.4.2 Gap Analysis 147
6.4.3 Opportunity 149
6.5 Non-hormonal Therapies 151
6.5.1 Unmet Needs 151
6.5.2 Gap Analysis 152
6.5.3 Opportunity 153
6.6 Better Understanding of the
Disease Etiology and Pathophysiology 154
6.6.1 Unmet Needs 154
6.6.2 Gap Analysis 155
6.6.3 Opportunity 155
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment